Atilmotin
Also known as: ATI-7505, motilin receptor agonist peptide
Source Atilmotin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Atilmotin is a synthetic motilin receptor agonist peptide developed as a prokinetic agent for gastroparesis and related gastric motility disorders. It was investigated as an alternative to erythromycin-based motilin agonists with potentially improved receptor selectivity and reduced tachyphylaxis.
Mechanism of Action
Selectively activates motilin receptors (MLN1) in the gastrointestinal tract, stimulating coordinated antral and duodenal contractions to accelerate gastric emptying and promote gastrointestinal motility
Routes of Administration
Goals & Uses
- Gastroparesis treatmentGastrointestinal MotilityModerate
- Postoperative ileus preventionGastrointestinal MotilityLow
- Gastroesophageal refluxGastrointestinal MotilityLow
Contraindications
- Known hypersensitivity to atilmotin or motilin analoguesAllergyHigh
- Gastrointestinal obstructionStructural GI DisorderHigh
Adverse Effects
- Injection site reactionsLocalCommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- TachyphylaxisPharmacodynamicUncommon
- DiarrheaGastrointestinalUncommonLoose or frequent stools
- Abdominal crampingGastrointestinalCommon
Drug Interactions
- Anticholinergic agentsModerate
- Opioid analgesicsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
Regulatory Status
- European UnionInvestigationalNo marketing authorisation granted; early-phase studies conducted
- United StatesInvestigationalInvestigated under IND; no approved indication; development status uncertain
- United KingdomUnknownNo known regulatory submission or approval
Atilmotin has not received regulatory approval in any major jurisdiction. Development was conducted primarily in preclinical and early clinical research settings; no NDA or MAA filing is known to have been completed.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Atilmotin?
Atilmotin is a synthetic motilin receptor agonist peptide developed as a prokinetic agent for gastroparesis and related gastric motility disorders. It was investigated as an alternative to erythromycin-based motilin agonists with potentially improved receptor selectivity and reduced tachyphylaxis.
What is Atilmotin used for?
Atilmotin is educationally associated with: Gastroparesis treatment, Postoperative ileus prevention, Gastroesophageal reflux. Educational only — not medical advice.
How is Atilmotin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Atilmotin?
Reported adverse effects include: Injection site reactions, Nausea, Tachyphylaxis, Diarrhea, Abdominal cramping. This list is not exhaustive — consult a qualified clinician.
Who should avoid Atilmotin?
Recorded contraindications: Known hypersensitivity to atilmotin or motilin analogues, Gastrointestinal obstruction. Consult a qualified clinician before use.